News&Media

Capital Cell, Europe’s leading equity crowdfunding platform specialized in biomedicine, has closed financing rounds for a total of 19 companies during 2021. Among the funded projects Amadix stands out, being the largest round closed with a total of 1.97 million raised.

AMADIX strongly believes that prevention is key to extend people’s life. In cancer, prevention is the best way to reduce the chances of having cancer. PREVECOLl® is an AMADIX’ blood-based test for colorectal cancer detection.

Rocío Arroyo, researcher, and CEO of Amadix, leads the team that has created an innovative blood-based test that can detect if a healthy person will develop a malignant colon tumour in the future. As an entrepreneur, Rocío turned her scientific knowledge into a viable business model securing private investors in Castile and Leon to found

Amadix and other entities participate in the Meeting Day organized by Grupo de Mujer y Ciencia de la SEBBM, AseBio, ASEICA-Mujer y el Museo Nacional de Ciencias Naturales (MNCN-CSIC) and United Nations on occasion of the International Day of the Girl and Women in Science. All the participants thanked Queen Letizia for her support of

EIC Accelerator is the biggest funding round supported by the European Commission, with a total budget of 637 million euros and more than 90 million euros to be distributed between the 11 Spanish start-ups selected, including Amadix. To be part of the EIC Accelerator is a big boost for the company and the commercialization of

This year, the specialized magazine has selected 22 people, including Rocío Arroyo, who stand out for their talent, leadership, productivity, and power to change the world. Rocío Arroyo has been distinguished by her professional career as scientific, researcher and entrepreneur in the oncologic field with the development of early cancer detection tests by Amadix.

As an example: biotech companies in Spain are about 900, and 90% of them are SME and micro-SME, and their product development phases are very long, they need a lot of input of resources. Hence, these companies require very specific instruments of financing.

Despite the pandemic, oncology still being the therapeutic area with the highest level of investigation among AseBio’s partners. Up until 72% of the new cancer treatments are developed thanks to biotechnology and the sector became key, considering that the number of diagnostics decreased due the health crisis according to SEOM’s data. Amadix’ CEO, Rocío Arroyo,

AMADIX received the award for the best start-up at South Summit 2018 South Summit is the largest international event in southern Europe, bringing together entrepreneurs, investors, start-ups and corporations, in which more than 3,000 disruptive start–ups have participated from 84 countries. In addition, AMADIX was selected and participated in an Immersion Program in the USA